Answers are grounded in this paper and cite their sources.
We would like to thank Dr. Nickel for his comments (J. Curtis Nickel (2020) It is premature to categorize Hunner Lesion interstitial cystitis as a distinct disease entity, Scandinavian Journal of Urology, 54:2, 99-100, DOI: 10.1080/ 21681805.2020.1744714) regarding our publication: Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: an ESSIC working group report in SCANDINAVIAN JOURNAL OF UROLOGY 2020, VOL. 54, NO. 2, 91–98 https://doi.org/10.1080/21681805.2020.1730948. We disagree with him vehemently. It has been 33 years since Fall and coworker’s paper ‘Chronic interstitial cystitis: a heterogeneous syndrome’ which described ‘marked clinical differences between ulcerative and nonulcerative interstitial cystitis’ [1] appeared in the literature. This was the first publication to call for evaluating these conditions separately in clinical studies and noted the different clinical pathways for treatment. Much literature has been published to support this concept. Failure to act earlier is a major reason that no new treatments have been found effective enough to warrant FDA approval since the 1996 approval of sodium pentosan polysulfate (Elmiron), which itself has failed two subsequent phase-four clinical efficacy trials. While the symptoms of Hunner lesion positive and negative patients may be similar, that is no reason not to continue the efforts to phenotype the disorder and discover what treatments may benefit individual phenotypes. The one phenotype we have that can be applied today is the Hunner lesion for the numerous reasons noted in our publication and supported by much of the cited recent literature [2,3]. We can all agree that, though recurrent urinary tract infection, radiation cystitis, ketamine cystitis, and even overactive bladder may have similar presentations, we would not lump them together in clinical trials or use similar treatment algorithms. Medicine is not a perfect science and things do change. We would expect that a symptom-based syndrome would over time yield new phenotypes based on etiology, new biomarkers, pathology, response to different therapies, etc. As new knowledge is gained our care of patients will evolve. At this point in time, denying the current evidence and continuing upon our current unproductive pathways makes no sense, especially for the patients who depend on us. It is time that Hunner lesion took its place as a specific disease that can be diagnosed and treated apart from the general symptom-based syndrome of BPS/IC. Disclosure statement
No takes yet. Share an insight, caveat, or question.
Fall et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: